An evaluation of the quality of evidence underpinning diabetes management models: a review of the literature by Schofield, D et al.






Background: There is a paucity of research on the quality of evidence relating to primary care workforce models. 
Objective: To evaluate the quality of evidence on diabetes primary care workforce models in Australia. 
Methods: The NHMRC’s (2000, 2001) frameworks for evaluating scientific evidence and economic evaluations were used to assess the quality of studies involving primary care workforce models for diabetes care involving Australian adults. A search of medical databases (MEDLINE, AMED, RURAL, Australian Indigenous HealthInfoNet, and The Cochrane Institute), journals for diabetes care (Diabetes Research and Clinical Practice, Diabetes Care, Diabetic Medicine, Population Health Management, Rural and Remote Health, Australian Journal of Primary Health, PLoS Medicine, Medical Journal of Australia, BMC Health Services Research, BMC Public Health, BMC Family Practice), and Commonwealth and State Government health websites was undertaken to acquire Australian studies of diabetes workforce models published 2005 to 2013. Various diabetes workforce models were examined, including “one-stop shops”, pharmacy care, Aboriginal services, and telephone-delivered interventions. The quality of evidence was evaluated against several criteria, including relevance and replication, strength of evidence, effect size, transferability and representativeness, and value for money.
Results: Of the14 studies found, 4 were randomised controlled trials and 1 was a systematic review i.e. Level II and I (best) evidence. Only 3 provided a replicable protocol or detailed intervention delivery. 11 lacked a theoretical framework.12 reported significant improvements in clinical (patient) outcomes, commonly HbA1c, cholesterol, and blood pressure; only 4 reported changes in short- and long-term outcomes (such as quality of life). Most studies used a small or targeted population. Only 2 studies assessed both benefits and costs of their intervention compared to usual care, and cost effectiveness.
Conclusions: More rigorous studies of diabetes workforce models are needed to determine whether these interventions improve patient outcomes and, if they do, represent value for money. 
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What is known about the topic? Although health systems with strong primary care orientations have been associated with enhanced access, equity and population health, the primary care workforce is facing a number of challenges. These include a mal-distribution of resources (supply-side) and health outcomes (demand-side), inconsistent support for teamwork care models, and a lack of enhanced clinical inter-professional education/training opportunities.  These challenges are exacerbated by an ageing health workforce and general population, as well as a population that has increased prevalence of chronic conditions and multi-morbidity. Although several policy directions have been advocated to address these challenges, there is a lack of high-quality evidence about which primary care workforce models are best (and which models represent better value for money than current practice), and what the health effects are for patients.

What does this paper add? This study demonstrated a number of strengths and weaknesses of Australian diabetes models of care studies. In particular, only five of the 14 studies assessed were  designed in a way that enabled them to achieve a Level II or I rating (and hence the “best” level of evidence), based on the NHMRC’s (2000, 2001) frameworks for assessing scientific evidence. The majority of studies risked the introduction of bias, and thus may have incorrect conclusions. Only a few studies described clearly what the intervention and the comparator were, and thus could be easily replicated. Only two studies included cost effectiveness studies of their interventions compared to usual care.




























Although health systems with strong primary care orientations have been associated with improved access, equity and population health1, the primary care workforce is currently facing significant challenges. These include a mal-distribution of resources (supply-side) and health outcomes (demand-side), inconsistent support for teamwork care models, and a lack of enhanced clinical inter-professional education/training opportunities.  These challenges are exacerbated by an ageing health workforce, and an ageing general population that has increased prevalence of chronic conditions and multi-morbidity.2

Novel health workforce models have been advanced as a way forward to address these challenges, and growing patient, and wider health system, demands through new roles (e.g. Nurse Practitioners), support roles (e.g. Allied Health Assistants) which may substitute for current forms of service delivery, or enhanced roles (e.g. diabetes nurses). Approaches to improve the retention of primary healthcare workers through organisational policies, increase the efficiency of the current skills mix, or improve productivity through linking pay to performance have also been advanced. Although several policy directions have been advocated, there is a lack of evidence about which primary care workforce models are best, and what the health effects are for patients.3,4

The lack of evidence to support these new directions in primary care is surprising, since it is widely acknowledged in medicine (and public health) that evidence-based medicine essential to reduce the introduction of ineffective and expensive medical treatments.5  

In this paper, we draw on the National Health and Medical Research Council’s (2000, 2001) frameworks for assessing the quality of scientific evidence (and economic evaluations)6,7 to evaluate the quality of evidence on primary care workforce models for diabetes care.


2.   The NHMRC’s (2000, 2001)6,7 frameworks for evaluating the quality of scientific evidence with examples from primary care workforce models
 
To make a decision about whether to introduce a new care model it is important to be familiar with the quality of the evidence surrounding that model. In particular, whether the care model (intervention) is likely to achieve the aims of the intended model and whether it represents value for money.6 

A set of criteria established by the NHMRC (2000, 2001) to assess medical/public health research is used in this paper to appraise diabetes primary care workforce models.6,7 These criteria are summarised in Table 1. The first is whether the study states clearly what health outcomes may be achieved by the particular intervention, and whether these outcomes have been measured in appropriate units.  For example, whether the new primary care model was intended to improve health outcomes or save money but produce no worse health outcomes (non-inferiority). Additionally, the study needs to have a reasonable hypothesis and scientific explanation with evidence (and perhaps a theoretical model) underpinning it – information which can be used to explain why the desired effect is expected from the model.

The design of studies can vary markedly.  The highest quality of evidence, as classified by the NHMRC, comes from systematic reviews of randomised controlled trials (RCTs) (Level I).  Systematic reviews determine whether a treatment effect can be replicated and, by pooling the results of RCTs, provides a best estimate of the magnitude of the effect.7 The second level of evidence comes from a well-designed RCT, which has the strength of minimising bias (Level II). Pseudo RCTs, comparative studies, case control studies or cohort studies have the potential to introduce bias and are ranked as Level III. Case series (pre and post test studies) suffer from problems related to the lack of randomisation (such as non-comparability of control and treatment groups, different outcome measures for the two groups) and are ranked as Level IV. The lowest level, now excluded by the NHMRC, is expert opinion and consensus from expert committees because these sources do not have a scientific basis (Level V).


Whilst a study may report a statistically significant effect, it is important to ascertain whether the effect is clinically important. In relation to diabetes care, for example, we would want to know what the cut-off was for scale weight loss to be regarded as clinically important (i.e. losing how many kilograms would be considered as clinically significant). In this case, it would also be important to know whether the difference in this outcome was sustained over time or became insignificant between the intervention and control groups. Although studies may clearly state what the benefits (health outcomes) are for patients, it is important that they also state what the harms (costs) are for patients (and funders). Information on relevant benefits and costs of interventions are needed to undertake an overall (economic) evaluation. 

As funding becomes increasingly scarce, due to governments continuously running deficits (as they try to cope with an ageing population) and external challenges (such as the Global Financial Crisis, GFC), ensuring that only new healthcare models which represent efficacy as well as efficiency are implemented is crucial.


Table 1: A framework for assessing the quality of evidence relating to primary care workforce models. Source: NHMRC (2000, 2001).

Evidence	Purpose
Relevant and replicable	Did the study identify clinical outcomes that are appropriate and relevant?Is the study design stated clearly enough so that it could be replicated?
Theoretical framework	Is there a logical (scientific) reason why the primary care workforce model (intervention) will have the desired effect?
Strength of the evidence	Is it a robust study design?Level I Systematic reviews of randomised controlled trials (RCTs).Level II A well-designed RCT.Level III Pseudo RCTs, comparative studies, case control studies, cohort studies.Level IV Evidence from case series such as pre and post studies.Level V Expert Opinion.    
Size of the effect	Did the p-value or confidence interval reasonably exclude chance? Is the effect size clinically important?
	
Transferable and representative	What are the benefits and harms (costs) of the intervention and the comparator? Do they differ between patient groups?Is the study population representative of the population in which the primary care workforce model will be implemented?
Duration	Is the effect sustained over a relevant time horizon?
Value for money	Is the new primary care workforce model cost effective relative to standard care?


3.   Assessing the quality of evidence relating to diabetes primary care workforce models
 
An appraisal of primary care workforce models applied to diabetes care in Australia published in peer reviewed and ‘grey’ literature between 2005 and 2013 was undertaken. Three main areas were searched:

	Key medical databases (MEDLINE, AMED, RURAL, Australian Indigenous HealthInfoNet, and The Cochrane Institute); 
	Key academic peer review journals (Diabetes Research and Clinical Practice, Diabetes Care, Diabetic Medicine, Population Health Management, Rural and Remote Health, Australian Journal of Primary Health, PLoS Medicine, Medical Journal of Australia, BMC Health Services Research, BMC Public Health, BMC Family Practice) relating to diabetes models of care; and
	A number of key Australian (Commonwealth and State Government) health websites (Australian Government Department of Health, http://www.health.gov.au/ (​http:​/​​/​www.health.gov.au​/​​); Australian Government Department of Health and Ageing, http://www.yourhealth.gov.au/internet/yourhealth/publishing.nsf/content/home (​http:​/​​/​www.yourhealth.gov.au​/​internet​/​yourhealth​/​publishing.nsf​/​content​/​home​); Government of Western Australia Department of Health http://www.health.wa.gov.au/home/ (​http:​/​​/​www.health.wa.gov.au​/​home​/​​)).

Key search terms were “primary workforce”, “workforce models”, “diabetes”, “care models”, and “Australia”.
The NHMRC’s (2000, 2001)6,7 frameworks for assessing evidence (see Table 1) were applied to the studies we found involving primary care workforce models designed to improve the health of adults with diabetes. Of the 14 studies found, only five could be classified as RCTs or systematic reviews and thus correspond to the “best” type of evidence (Level II or I). Nine studies constituted “evidence from case series” or “expert opinion” (Level IV or V). Of the higher-rated studies, one study (Graves et al 2009)8 incorporated an economic evaluation (cost-effectiveness analysis) within the RCT and another (Dennis et al 2008)9 was a systematic review. Note that Graves et al (2009)8 is rated II* rather than simply II because it not only meets the NHMRC’s (2000)7 standard for Level II evidence (i.e. a properly designed RCT) but it includes an economic evaluation. 

All studies provided some information about study design and expected outcomes; however, only three studies (Clifford and Davis (2005)10, Krass et al (2007)11, Graves et al (2009)8) provided a replicable protocol or detailed information about intervention delivery. Thirteen studies lacked a theoretical framework. Only four studies (Laatikainen et al (2007)12 and Kilkkinen et al (2007)13, Foster et al (2008)14, and Graves et al (2009)8) provided sufficient detail about the intervention. 

Most studies identified, measured and valued the benefits of their particular intervention; however, only three studies (McRae et al (2008)16, McDermott and Segal (2006)17, Graves et al (2009)8) identified, measured and valued the related costs. Only two of these studies (McDermott and Segal (2006)17), Graves et al (2009)8) had collected the type of data required to undertake an economic evaluation and thus determine whether the intervention represented value for money compared to the comparator (usual care).

Table 2 is a summary of the 14 studies found. The quality of each study was rated on the basis of the NHMRC’s (2000, 2001) criteria for assessing evidence (see column 4). The diabetes primary care workforce models are grouped under 5 headings: one-stop shops, Pharmacy models, Aboriginal Services, Telephone delivered Interventions and Systematic Reviews, which characterise the models implemented. Of the 14 studies, 12 reported statistically significant improvements in several immediate health outcomes (such as HbA1c) of patients with diabetes. Three studies (Rasekaba et al (2012)15, Clifford and Davis (2005)10 and Graves et al (2009)8) stated clearly what type of changes in health outcomes equated to “clinically important” ones. Only four studies (McRae et al (2008)16, Clifford and Davis (2005)10, McDermott and Segal (2006)17, Graves et al (2009)8) assessed changes in both short- and long-term health outcomes. Most studies used either a small (cut-off was n ~ 100) or very specific population such as diabetic patients in a rural community. 


The “One-Stop Shop” or co-ordinated diabetes treatment

Of the seven studies in this group, five were given a quality rating of IV or IV* and two were given a rating of V. The first five studies (Shephard et al (2005)18, Laatikainen et al (2007)12 and Kilkkinen et al (2007)13, McRae et al (2008)16, Li Wai Suen et al (2012)19, Raeskaba et al (2012)15) analysed clinical data from interventions whereas the last two studies (WA Department of Health (2008)20, Foster et al (2008)14) were primary care policy papers. The first five studies provided a sufficient amount of information regarding health outcomes (such as H1bA1c and quality of life) to conclude they were both appropriate and relevant. Only one (observational) study (McRae et al (2008)16) also provided information about costs; however, this was limited to the intervention only (as there was no control group) and used to conduct a cost-impact analysis. All studies described the state of existing evidence on the effectiveness of similar interventions in different disease populations (Li Wai Suen et al (2012)9) or research demonstrating a link between their intervention and the desired effects in diabetic patients. Only the Greater Green Triangle (GGT) diabetes prevention project (Laaikainen et al (2007)12 and Kilkkinen et al (2007)13) provided details about an earlier implementation of their intervention (pilot). All studies reported changes in clinical outcomes that were statistically significant for patients in the intervention group. Foster et al (2008)14 only reported ‘outcomes’ on hypothetical case studies i.e. no patients actually experienced the incentives. The transferability of study findings is questionable, since these studies relied on small samples (Shephard et al (2005)19 and Li Wai Suen et al (2012)19) or specific populations (i.e. rural communities, socioeconomically disadvantaged groups). Only one study (McRae et al (2009)16) projected the occurrence of health outcomes to several decades.

Pharmacy diabetes care programs
 




















Table 2. Summary of primary level models of diabetes care
Model of care (study and brief description)	Relevant and replicable	Theoretical framework	Strength of evidence	Size of main effects	Transferable and representative	Effect time	Value for money
One stop shop							
Point of Care Testing (POCT) Shephard et al (2005)18Standard “disjointed and uncoordinated” care versus a multidisciplinary “one-stop” GP, diabetes educator, podiatrist and nurse service.	Provided few details of the intervention.	-	IV A before and after study of patients with diabetes	Mean (SD) for HbA1c was 7.6% (1.6) at baseline and 7.1% (1.4) at most recent GP visit (p=0.03); cholesterol was 4.64 mmol/L (1.0) at baseline and 4.28 (0.9) at most recent GP visit (p=0.01); systolic blood pressure was 143 mmHg (21) at baseline and 134 (14) at most recent GP visit; diastolic blood pressure was 81 mmHg (21) at baseline and 76 (10) at most recent GP visit (p=0.09). 	Small sample size (n=54) in 7 rural communities.	10 months	No economic evaluation.
The Greater Green Triangle (GGT) diabetes prevention project  Laatikainen et al (2007)12 and Kilkkinen et al (2007)13Patients recruited in GP clinics using the Diabetes Risk Score tool for six group counselling sessions with study nurses, dietician and physiotherapist.	Yes, the intervention was based on a Finnish implementation study. The longitudinal study design used to examine changes in clinical outcomes was based on the design of a previous implementation trial. 	Yes, based on a Finnish implementation study.	IVA pre and post test study.	Significant reductions in mean weight by 2.52 kg [95% CI 1.85 to 3.19], waist circumference by 4.17 cm [3.48 to 4.87], mean fasting plasma  glucose by 0.14 mmol/l [0.07 to 0.20], plasma glucose twohours after oral glucose challenge by 0.58 mmol/l [0.36 to 0.79], total cholesterol by 0.29 mmol/l [0.18 to 0.40], lowdensity lipoprotein cholesterol by 0.25 mmol/l [0.16 to 0.34], triglycerides by 0.15 mmol/l [0.05 to 0.24] and diastolic blood pressure by 2.14 mmHg [0.94 to 3.33] after 12 months.	Patients aged 40-75 years, with at least moderate risk of type 2 diabetes. Three rural communities in Southeast Victoria (n = 237).	12 months	No economic evaluation. 
Southern Highlands Division of General Practice (SHDGP) McRae et al (2008)16GPs used a database of SHDGP clinical data to co-ordinate care according to national guidelines.	Sufficient information to be replicated. Changes in short-term  (HbA1c, blood pressure, BMI, cholesterol) and long-term outcomes (e.g. QALE) examined. Costs were also counted. No formal control group.	-	IV*  Assessed costs and health outcomes.	Found asmall but statistically significant improvement in mean HbA1c over 5 years (6.9 at registration vs. 7.27.2 after 5 years) (p-value not reported).  Also found a significant reduction in lipid cholesterol level (6.1 at registration vs. 5.1 after 5 years) (p-value not reported).  	Only utilised one database from one division of General Practice in NSW.	Projected outcomes to 40 years.	Cost-impact analysis.
Multidisciplinary Diabetes Support Service (DSS) clinic, Melbourne Li Wai Suen et al (2012)19The clinic was designed to support primary care by providing rapid assessment and management plans (2-3 visits per patient with an endocrinologist, a diabetes nurse educator and a dietician) and with other specialists (podiatry, nephrology and ophthalmology) if necessary.	Provided information about patient visits and type of health professionals seen at the diabetes support service clinic.Only one clinical outcome considered (benefit) and no costs.No randomisation. No control group. 	-	IV A retrospective audit of the DSS clinic.	Reported a significant reduction in mean HbA1c of 1.5% for patients who visited the clinic. after a mean follow-up period of 4.4 months (i.e. mean HbA1c at the time of admission to the service was 9.2% vs. 7.7% at discharge, p<.0001).	Small sample. n = 115 complete medical records for patients who attended the DSS clinic at the Dandenong Hospital in Melbourne 2004-09.	4.4. months (mean follow up)	No economic evaluation.
Northern Alliance Hospital Admission Risk Program (NA-HARP) Rasekaba et al (2012)15 A multidisciplinary disease management program for patients with poorly controlled type 2 diabetes.	Study design outcomes were appropriate – HbA1c and Health-Related Quality of Life (HR-QOL). Sufficient information to be replicated (specified minimum number of visits/patient, skills-mix of the care team, length of stay in program capped at 12 months).  No costs, no randomisation (and thus no control group).	-	IVDesign not stated.	Reported statistically significant improvements in mean HbA1c (8.6% (SD 1.9) at enrolment Vs. 7.3% (SD 1.2) at 12 months (p<.001) and quality of life measures for patients (251 or 64% patients had improved HR-QOL, 27 or 7% had no change,and 114 or 29% had deteriorated quality of life) after 12 months. Overall, 68% of patients experienced improvements in HbA1c. Mean utility scores improved by 0.11 (p<.001) after 12 months. 	 545 patients who had HbA1c data at baseline and at 12 months. The program provided care to a socioeconomically disadvantaged population living in northern metro region of Melbourne.	12 months	No economic evaluation.
WA Department of Health (2008)20The Endocrine Network’s recommended diabetes model of care including GP-coordinated multidisciplinary care.  	High level of program description. The model is described in detail, including the roles of the WA Government and Divisions of General Practice.  Intended outcomes are described (such as reduced rates of diabetes, complications, reduced ED presentations and hospital admissions).	-	VA grey literature report.	 Nothing reported. 	Potentially high if the study were conducted state-wide	-	-
Enhanced Primary Care Foster et al (2008)14	Medicare Enhanced Primary Care programA number of potential adverse clinical outcomes of the program are identified and illustrative, hypothetical case studies claiming possible serious perverse incentives are discussed.  	- 	V A description of the Australian Government’s initiative to introduce chronic disease management items on Medicare, including referrals to up to five allied health treatments.	No real patients or health professionals in the study (and thus no clinical outcomes reported). Case studies were hypothetical. 	-	-	-
Pharmacy models							
The Freemantle Diabetes Study (FDS) Clifford and Davis (2005)10Pharmaceutical care patients with type 2 diabetes had face-to-face goal-directed medication and lifestyle counselling at baseline, 6 and 12 months and 6-weekly telephone assessments.	Defined protocol (RCT)	-	IIRCT	Statistically significant abd larger reductions in mean HbA1c for those in the intervention vs. control (-0.5% [95%CI -0.7 to -0.3] vs. 0 [-0.2 to 0.2] )and systolic (-14 mmHg [-19 to -9] vs. -7 [-11 to -2])and diastolic (-5 mmHg [-8 to -3] vs. -2 [-4 to 1]) blood pressure (p≤0.043).blood pressure. A reduction in the median (interquartile range) 10-year estimated risk of a first coronary heart disease event was found for patients in the intervention (25.1% [15.6 –36.2] to 20.3 [14.6 –30.2]; n=42,P=0.002) but not for those in the control (26.1% [17.2–39.4] vs. 26.4 [16.7–38.0]; n  52,p=0.17).	198 patients with type 2 diabetes from the FDS were randomised to pharmaceutical (92 patients) or usual care (88 patients).  	12 months for Hb1Ac and blood pressure. Projected first CVD event to 10 years.	No economic evaluation.
Pharmacy diabetes care program in four states Krass et al (2007)11Intervention pharmacists attended a 2 day workshop and patients made five visits to the pharmacy over six months. Those in the control had one visit at the beginning and another at end of the study.	Defined protocol (RCT). Study examined changes in clinical outcomes and quality of life measures for patients in intervention and control groups.	-	IIMultisite RCT.	.For patients in the intervention (n=149), there was a significant reduction in mean blood glucose level over the 6-month study from 9.4 to 8.5 mmol/l (p< .01). There was also a significantly greater improvement in glycaemic control in the intervention group compared to the control: the mean reduction in HbA1c in the intervention group was −0.97% [95% CI −0.8 to −1.14) vs. −0.27% [95% CI: −0.15 to −0.39] in the control. Reductions were also seen in systolic and diastolic blood pressure in the intervention group between baseline and follow-up, but when compared to the control group these decreases werenot statistically significant.	56 pharmacies (28 interventions and 28 controls)  and 289 patients in four Australian states (urban and rural settings) were involved in the study.  	6 months	No economic evaluation.
Aboriginal Services							
Quality Assurance for Aboriginal Medical Services (QAAMS) Point of Care Testing Program  Shephard (2006)21Delivery involved doctors, pathologists, Aboriginal Health Workers (AHWs) and allied health professionals.	Brief description of this feasibility/acceptability study was given	-	IVDesign not stated.	Both clinicians and patients reported improved satisfaction with delivery or consumption of diabetes services. A statistically significant reduction in HbA1c, from 9.3% (± 2.0) to 8.6% (± 2.0), was found in 74 patients 12 months after commencing  QAAMS point-of-care testing (p =.003).	Aboriginal rural communities	12 months	No economic evaluation.
McDermott and Segal (2006)17Direct costs and savings of new diabetes service implemented in 2000 were compared to usual care in the primary care setting from 2001 to 2006.	Discussed the type of health professionals delivering the new diabetes service, what patients were expected to experience. Outlined the different cost components and health outcomes (hospitalisations among people with diabetes for infections and other acute complications, lowerlimb amputations, end-stage renal disease and cardiovascular disease). 	-	IIA costing study.	Over the years 2000-05, a netpresent value cost of $570,000 was estimated for the new service. This was equivalent to A$1,800for each major event avoided.Showed that after 4 years of initiation, annual cost savings exceed annual program delivery costs.Estimated the number of hospitalisations averted among patients with diabetes due to improved diabetes care: 253 fewerserious foot infections requiring hospitalisationand possible amputation; At least 15 person-yearson dialysis averted; and 47 fewer serious CVD events (IHD and stroke) requiring hospitalisation.Significant reductions in mean systolic 1(39.40 (16.1) to 130.86 (19.1), p=.000) and diastolic (81.05 (9.3) to 75.97 (12.1), p=.000) blood pressure were found for patients during the period 2000 to 2003. 	A district health service in remote northern Australia, with 9,600 mainly Indigenous (Islander) residents, including 1,000 adults with known diabetes served by 21 primary care centres.	6 years (2000-05)	NPV calculated.
Flinders model of self-management support for patients with type 2 diabetes Battersby et al (2008)22AHWs carried out patient-centred, self-management assessment and care planning with patients. 	A good description of the roles of different health professionals involved in the program and outcomes measured.		IVA pilot study.	A statistically significant reduction in mean HbA1c after 12 months, dropping from8.74 to 8.09 (p<.01); no significant change in mean blood pressure after 12 months. AHWs found the program acceptable as did their patients. 	60 Aboriginal Australians with type 2 diabetes on Eyre Peninsular, SA. 	12 months	No economic evaluation.
Telephone delivered Interventions							
A cost-effectiveness study of the Logan Healthy Living Program (RCT) Graves et al (2009)8Telephone counselling versus usual care.	Study protocol provided. Immediate (physical activity and diet) and final benefits (QALYs) and various costs (such as staff costs and services used by patients) were included in the study.	The intervention was based on previous studies (cited).	II*A cost-effectiveness modelling study using RCT data. 	The means and 95% Bayesian credible intervals of incrementalcost and QALY outcomes for all comparisons was presented in the paper.  Choosing the Telephone Counselling intervention over Usual Carecosted $78,489 per QALY gained, choosing Telephone Counsellingover the existing practice alternative (Real Control) costed $29,375per QALY gained, and choosing Usual Care over existing practicealternative (Real Control) costed $12,153 per QALY gained.The modelling study showed that a decision to adopt a Telephone Counselling program over Usual Care had only a 38%  probability of being cost-effective, whereas adopting the intervention over existing practice (real control) had a 100% probability ofbeing cost-effective (as shown in cost-effectiveness acceptability curves). 	10 years	434 patients with type 2 diabetes or hypertension in a low socioeconomic area of Queensland (Logan).	Cost-effectiveness study.
RCTs or Systematic Reviews							





The 14 studies of diabetes primary care workforce models appraised in this paper suggest there is an urgent need for more rigorous research on this topic in Australia, especially in relation to the cost effectiveness of new interventions. Only five studies were designed in such a way as to achieve a Level II or I rating, based on the NHMRC’s (2000, 2001) frameworks for assessing scientific evidence. The majority of studies risked the introduction of bias, and may have made incorrect conclusions. A number of the diabetes primary care models were implemented in quite unique populations (i.e. small, culturally- or socioeconomically-defined) and hence it is difficult to say whether they (and the possible benefits they describe) could be transferred to the (general) population. Only a few studies described clearly what the intervention and the comparator were, and thus could be successfully replicated. Only two studies (McDermott and Segal 2006[17] and Graves et al 2009[8]) assessed the cost effectiveness of their intervention compared to (formal) usual care. 

The Commonwealth Government is currently piloting new approaches to diabetes management through general practice. It has recognised that benefits can be derived from well-coordinated, integrated, multidisciplinary diabetes care teams and, for this reason, in July 2011 the Government committed $30.2m over 3 to 4 years to a Coordinated Care for Diabetes Pilot in the primary care setting.[23]  The pilot is testing a model of prepaid funding for coordinated care of patients with diabetes in general practice.[24] With a superior study design it could generate vital information about the relative merits of the intervention in relation to patient outcomes.
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